ABSTRACT
@#Among the second round of “double first-class” construction universities, 12 universities are in the process of building first-class pharmaceutical and traditional Chinese medicine disciplines.The aim is to explore the innovative development trend of these 12 universities, based on their information related to pharmacy and traditional Chinese medicine in the past five years.The study used the PatSnap global patent database to search for pharmaceutical related patents applied by 12 universities from 2018 to 2022, and analyzed the information from perspectives such as application and authorization volume, technical themes, transfer and licensing status, and international patent situation.The results reveal that comprehensive universities and China Pharmaceutical University are superior to other pharmaceutical universities in terms of patent application volume and licensing rate.From the perspective of patent classification, most of the relevant patents involve the effective ingredients of drugs.Comprehensive universities and China Pharmaceutical University pay more attention to the research of anti-tumor drugs.Among all authorized patents, the quantity is insufficient, and most of them are exclusive licenses.The transfer of relevant rights mostly occurs between universities and enterprises.In terms of international patent applications, comprehensive universities dominate in terms of quantity, but the total amount is still insufficient.In the future innovation and development process of “double first-class” universities, it is necessary to improve the awareness of patent protection and layout, attract relevant talents, give full play to the advantages of university intellectual property information service centers, and promote the transformation of university achievements.
ABSTRACT
@#,Objective To analyze the current status and development trends of the patents of spleen-invigorating health food with the homology of medicine and food in China, and to provide ideas and references for the research and development of traditional Chinese medicine (TCM) spleen-invigorating health food with the homology of medicine and food. @*Methods@#The State Administration for Market Regulation website’s “Special Food Information Query Platform” and the incoPat global patent database were searched in this study. Based on the methods of bibliometrics, the registered health food and patents related to spleen-invigorating health food with the homology of medicine and food in China were sorted out. Furthermore, the research and development numbers, provinces, institutions, technology and efficacy classification, major drugs, active ingredients and others of invigorating spleen health food in China were analyzed, and filtered patent data were visualized and analyzed by R programming language and CytoScape software. @*Results@# A total of 285 patents of health food with the homology of medicine and food for invigorating spleen were included and analyzed. From 2012, the patent registration numbers of these spleen-invigorating health food with the homology of medicine and food increased significantly in China. Over the past 20 years, the top five provinces in terms of patent disclosures were Guangdong, Anhui, Jiangsu, Shandong, and Guangxi. It was found that the technical efficacy of over 20 patents was described as “immune enhancement” “digestion” “disease prevention”, etc. Patent applications were mainly aimed at the research and development of the preservation of food or ingredients, the specific therapeutic activity of compounds, and pharmaceutical preparations, which were led by corporation research and development registrations, and supplemented by applications from research institutions and individuals. Among the 285 patents, the top 10 raw materials of spleen-invigorating health food with the homology of medicine and food were Shanyao (Dioscoreae Rhizoma), Fuling (Poria), Shanzha (Crataegi Fructus), Baizhu (Atractylodis Macrocephalae Rhizoma), Chenpi (Citri Reticulatae Pericarpium), Dazao (Jujubae Fructus), Gancao (Glycyrrhizae Radix et Rhizoma), Fengmi (Mel), Maiya (Hordei Fructus Germinatus), and Dangshen (Salviae Miltiorrhizae Radix et Rhizoma). The main functions were to nourish spleen and replenish Qi, invigorate spleen and benefit lungs, nourish blood and promote fluid production, and nourish spleen and stomach. @*Conclusion@#The main drug composition and functional components of spleen-invigorating health food with the homology of medicine and food are relatively clear, and the technical effects of invigorating the spleen and stomach, eliminating accumulation of food, and enhancing immunity are highly targeted. This paper provides evidence for the research and development, mechanism research, and process improvement of spleen-invigorating health food with the homology of medicine and food in the future.
ABSTRACT
Objective:To analyze the patent development status of 13 general hospitals in Beijing, for reference in promoting the management and translation of intellectual property rights of public hospitals.Methods:13 tertiary general hospitals in Beijing as one of the top 100 hospitals in China in terms of science and technology evaluaton metrics in 2020 were selected as the research subjects. The patent application and authorization information of 13 hospitals was retrieved from the IncoPat technology innovation intelligence platform, during the period from January 1, 2012 to December 31, 2021. The patent application and authorization status, international patent classification distribution, inventor information, patent validity, and registration of patent transfer were analyzed.Results:The numbers of patent applications and authorizations from 13 hospitals increased from 123 and 13 in 2012 to 2 053 and 2 368 in 2021, respectively. From 2012 to 2021, 13 hospital applied for 10 050 patents and authorized 6 896 patents, including 906 authorized invention patents, 5 863 utility model patents, and 127 appearance design patents. Valid patents amounted to 5 925, accounting for 85.92%, and valid authorized invention patents amounted to 796, accounting for 13.43%. 110 of these patents were transferred or licensed, accounting for 1.60% of the authorized patents.Conclusions:Aapplied and authorizated patents were rising year by year, but the ratios of invention patents and patient translation remained at a low level. The author suggestted that hospitals should highlight the value orientation of patents, strengthen-industry-academia-research cooperation, establish a professional management team and standardized management system for intellectual property, cultivate high-value patents, conduct pre patent application evaluation and screening, and improve patent conversion and technological innovation capabilities.
ABSTRACT
Objective:To explore the prescription and medication law of Traditional Chinese Medicine (TCM) compounds in the treatment of vascular dementia (VD) based on patent database.Methods:TCM compounds with patents about VD were retrieved from Chinese patent announcement website of the State Intellectual Property Office and CNKI. The retrieval time was from the establishment to the databases to 31 st, March 2022. The frequency, clusteringand association analysis were carried out with the help of TCM inheritance auxiliary platform (V2.5). The medication law was analyzed. Results:154 TCM compound patents for the treatment of vascular dementia were screened, involving 227 kinds of Chinese materia medica. Among them, Acori Tatarinowii Rhizoma (44 times, 28.57%) was used more frequently, and the common medicinal pair was Salviea Miltiorrhizae Radix et Rhizoma- Acori Tatarinowii Rhizoma (17 times, 11.03%). The medicinal property was mainly warm, the taste was mainly sweet, and the meridian was mainly liver meridian. Those with high confidence based on association rules were " Corni Fructus -Acori Tatarinowii Rhizoma" (0.90), " Corni Fructus -Rehmannize Radix et Praeparata" (0.90). Based on the complex network, it was concluded that the core drugs were 14 groups such as " Rehmannize Radix et Praeparata- Cistanches Herba- Corni Fructus". The new prescriptions extracted by entropy cluster analysis included 7 groups such as " Rehmannize Radix et Praeparata, Cistanches Herba, Corni Fructus and Asparagi Radix". Conclusion:The treatment of VD by TCM compounds with national patents is mainly based on tonifying deficiency, promoting blood circulation and removing blood stasis, eliminating phlegm and dampness, expelling wind and dredging collaterals, opening orifices and resuscitation, which can provide reference for clinical practice and new drug research and development.
ABSTRACT
The patents of acupuncture and moxibustion in China and abroad was analyzed, aiming to provide support for the innovative development of acupuncture industry. With the China Think Tank of Patent of Traditional Chinese Medicine and the PatSnap database as data sources, based on the mathematical statistics method, the application trend, legal status, patent types, transformation and distribution of major technical fields of acupuncture patents in China and abroad were analyzed. As a result, a total of 53,422 acupuncture patents were screened, involving 49 countries and 4 organizations. The patent types were mainly utility model patents. Although the application number of acupuncture patent had increased rapidly, the average patent conversion rate was generally low, approximately 4%. In the context of global economic integration, the acupuncture industry is developing at a high speed. It is suggested to take advantage of the "Belt and Road Initiative" to improve the international acceptance of acupuncture and moxibustion, adhere to the principle of attaching equal importance to the number and quality of patents, promote the in-depth cooperation of industry-university-research, and promote high-quality development of acupuncture and moxibustion.
Subject(s)
Humans , Moxibustion , Acupuncture Therapy , China , Medicine, Chinese Traditional , Databases, FactualABSTRACT
Diabetes mellitus is a chronic disease, typified by hyperglycemia resulting from failures in complex multifactorial metabolic functions, that requires life-long medication. Prolonged uncontrolled hyperglycemia leads to micro- and macro-vascular complications. Although antidiabetic drugs are prescribed as the first-line treatment, many of them lose efficacy over time or have severe side effects. There is a lack of in-depth study on the patents filed concerning the use of natural compounds to manage diabetes. Thus, this patent analysis provides a comprehensive report on the antidiabetic therapeutic activity of 6 phytocompounds when taken alone or in combinations. Four patent databases were searched, and 17,649 patents filed between 2001 and 2021 were retrieved. Of these, 139 patents for antidiabetic therapeutic aids that included berberine, curcumin, gingerol, gymnemic acid, gymnemagenin and mangiferin were analyzed. The results showed that these compounds alone or in combinations, targeting acetyl-coenzyme A carboxylase 2, serine/threonine protein kinase, α-amylase, α-glucosidase, lipooxygenase, phosphorylase, peroxisome proliferator-activated receptor-γ (PPARγ), protein tyrosine phosphatase 1B, PPARγ co-activator-1α, phosphoinositide 3-kinase and protein phosphatase 1 regulatory subunit 3C, could regulate glucose metabolism which are validated by pharmacological rationale. Synergism, or combination therapy, including different phytocompounds and plant extracts, has been studied extensively and found effective, whereas the efficacy of commercial drugs in combination with phytocompounds has not been studied in detail. Curcumin, gymnemic acid and mangiferin were found to be effective against diabetes-related complications. Please cite this article as: DasNandy A, Virge R, Hegde HV, Chattopadhyay D. A review of patent literature on the regulation of glucose metabolism by six phytocompounds in the management of diabetes mellitus and its complications. J Integr Med. 2023; 21(3): 226-235.
Subject(s)
Humans , PPAR gamma/metabolism , Curcumin/therapeutic use , Phosphatidylinositol 3-Kinases , Diabetes Mellitus/drug therapy , Hypoglycemic Agents/pharmacology , Hyperglycemia/drug therapy , GlucoseABSTRACT
Resumen Ante la transición a universidades emprendedoras, existe la tendencia a incrementar el patentamiento, aunque sin un estudio profundo del potencial comercial, por lo que el porcentaje de los productos que lo logran es muy bajo. El objetivo de esta investigación fue diseñar una estrategia de evaluación tecnológica y comercial de patentes universitarias a partir de la identificación de oportunidades en transferencia de tecnología (TT). Para ello, se examinaron 269 solicitudes de patente de la Benemérita Universidad Autónoma de Puebla (BUAP) y de la Universidad Autónoma del Estado de Morelos (UAEM), de acuerdo con la Clasificación Internacional de Patentes (CIP), en un periodo de 10 años (2009-2018), mediante 4 pasos: (a) construcción de la base de datos con la herramienta del Instituto Mexicano de Propiedad Intelectual, (b) identificación de las capacidades inventivas, a través de la Organización Mundial de la Propiedad Intelectual, (c) distribución por industrias de intensidad y oportunidad de mercado tecnológico, de acuerdo con la Organización para la Cooperación y el Desarrollo Económicos, y (d) análisis del comportamiento del mercado, mediante el estudio de las 36 solicitudes del área farmacéutica de ambas universidades. Los resultados mostraron que el 68.4 % de la BUAP y 75.6 % de la UAEM presentan un posicionamiento competitivo predominante en industrias de alta y mediana-alta tecnología. La ventaja de la herramienta propuesta es que permite reconocer la oportunidad del mercado tecnológico a partir de la construcción de escenarios relacionados con el comportamiento de la CIP.
Abstract Given the transition to entrepreneurial universities, there is a tendency to increase patenting, although without a deep study of the commercial potential. Therefore, the percentage of those developments that succeed is very low. The objective of this research was to develop a strategy for the technological and commercial evaluation of university patents, based on the identification of commercial opportunities in technology transfer (TT). Patent applications from the Benemerita Universidad Autonoma de Puebla (BUAP) and the Universidad Autonoma del Estado de Morelos (UAEM) were used for the study. The methodology consisted of the analysis of 269 patent applications in a period of 10 years 2009-2018, in accordance with the statistical International Patent Classification (IPC), through 4 steps: (a) construction of the patent database, with the use of the patent tool of the Mexican Institute of Intellectual Property, (b) identification of inventive capabilities, through the World Intellectual Property Organization, (c) distribution by industries of intensity and technological market opportunity, with the tool of the Organization for Economic Cooperation and Development, and (d) analysis of market behavior, through the study of the 36 applications of the pharmaceutical patent area, from both universities. The results showed that 68.4 % of BUAP and 75.6 % of UAEM reflected a predominantly competitive positioning in high technology and medium-high technology industries. The advantage of the proposed tool is that it allows the recognition of the technological market opportunity based on the construction of scenarios related to the IPC behavior.
ABSTRACT
Objective:The medical-related patent transformation level is relatively low in China for a long time. However, with the support and advancement of a series of national policies, domestic patents and other medical intellectual property projects are increasing year by year, and medical transformation is also receiving more and more attention. Zhongshan Hospital affiliated to Fudan University actively promotes the transformation of hospital patents through various channels, and actively explores how to carry out patent transformation and how to improve the success rate of transformation. This article aims to analyze and explore the feasibility of multi-channel promotion of patents, and to open up a new path for the use of new media to promote patent conversion.Methods:Through Excel analysis of " Zhongshan Patent Hero Post" WeChat public account and official Weibo platform weekly page views data and patent salon project data, as well as the patent application and transformation of Zhongshan Hospital in the past 6 years, and analyze the effect of patent promotion.Results:Through multiple channels and various links of effective promotion methods, the patent application and conversion situation of Zhongshan Hospital has doubled in the past 6 years.Conclusions:The hospital will further actively explore the patent application and transformation process, the full-cycle promotion method of each link, and provide a transfer and transformation consulting docking and promotion platform for the scientific research results or patent technologies related to hospitals and enterprises, and help the transformation of medical patents.
ABSTRACT
Alkannin/shikonin (A/S) and their derivatives are naturally occurring naphthoquinones majorly found in Boraginaceae family plants. They are integral constituents of traditional Chinese medicine Zicao (roots of Lithospermum erythrorhizon). In last two decades significant increase in pharmacological investigations on alkannin/shikonin and their derivatives has been reported that resulted in discovery of their novel mechanisms in various diseases and disorders. This review throws light on recently conducted pharmacological investigations on alkannin/shikonin and their derivatives and their outputs. Various analytical aspects are also discussed and brief summary of patent applications on inventions containing alkannin/shikonin and its derivatives is also provided.
ABSTRACT
OBJECTIVE To know about the development trend of small nucleic acid drugs in the world ，to provide reference for the research and development of small nucleic acid drug in China. METHODS By searching the academic literature and patents related to small nucleic acid drugs through the Web of Science literature database and PatSnap patent database from Jan. 1980 to Dec. 2021，research and development situation of small nucleic acid drugs were revealed comprehensively by analyzing research enthusiasm，R&D countries ，R&D institutions and technical topics of small nucleic acid drugs. RESULTS & CONCLUSIONS A total of 59 819 documents and 37 645 patent groups were included. The global trend of small nucleic acid drug literature publication and patent application could be divided into three stages. From 2003 to 2021，the research enthusiasm for small nucleic acid drugs continued to increase. The United States ，China，Japan and Germany were the main research and development countries for small nucleic acid drugs. The number of document publications （25 703，15 927 papers）and patent applications （14 240、8 937 groups） in the United States and China were ahead of other countries ，and the research and development activities were relatively strong. Moreover，the number of document publications and patent applications in China in this field had grown rapidly in recent years. The R&D institution with the largest number of publications was the University of California （2 499 papers），the R&D institution with the largest number of patent applications was the American Ionis Corporation （1 378 groups），and the Chinese Academy of Sciences （1 580 papers）had been shortlisted among the top 10 document producing institutions in the world. However ，our country ’s research and development in this field are mostly based on basic research ，and the research on industrial application is slightly insufficient. The research focus in the field of small nucleic acid drugs mainly focuses on nucleic acid sequences and their modification and improvement and drug loading technology. RNA interference technology has gradually become a hot technology for small nucleic acid drugs.
ABSTRACT
In Brazil, if patent prosecution takes more than 10 years, this extra period is added to the regular 20-year term. This paper analyses all pharmaceutical patents granted by the Brazilian National Institute of Industrial Property (INPI) with term extension and later discusses some intellectual property and health policy implications. On average, pharmaceutical patent applications wait seven years after substantive examination is requested before being examined, which takes only three and a half years. Furthermore, the role of the Brazilian Health Regulatory Agency (Anvisa) in providing prior consent has a marginal effect in prolonging the prosecution. Therefore, the extension of pharmaceutical patents' term is caused by the number of pending applications per examiner, which halts the prosecution for double the time it takes to examine the applications. Thus, proper solutions should focus on reducing the backlog per examiner at the INPI, which has caused the extension of 92% of the pharmaceutical patents in three and a half years, on average. We concluded that the Brazilian pharmaceutical patenting policy is biased towards the patentee. This imbalance will only be effectively corrected when the INPI is financially and administratively autonomous to reduce the ratio between the pharmaceutical patent application backlog and the number of examiners.
No Brasil, quando a tramitação de uma patente demora mais de 10 anos, esse tempo adicional é acrescentado à vigência regular de 20 anos. Este artigo analisa todas as patentes farmacêuticas concedidas pelo Instituto Nacional de Propriedade Industrial (INPI) com prorrogação de prazo, e em seguida discute algumas implicações para políticas de propriedade intelectual e de saúde. Em média, os pedidos de patente farmacêuticas esperam sete anos entre o requerimento do exame e o início da análise, que leva apenas três anos e meio. Além do mais, o papel da Agência Nacional de Vigilância Sanitária (Anvisa) na anuência prévia tem efeito marginal sobre o período de tramitação. Portanto, a extensão da vigência das patentes farmacêuticas é provocada pelo alto número de pedidos pendentes por examinador, o que atrasa em até duas vezes o tempo que leva para examinar os pedidos. Logo, soluções adequadas devem focar na redução do acúmulo de pedidos pendentes por examinador no INPI, que causou a extensão de 92% das patentes farmacêuticas em três anos, em média. Conclui-se que a política brasileira para patentes farmacêuticas apresenta um viés em favor do titular da patente. Esse desequilíbrio só será sanado efetivamente quando o INPI tiver autonomia financeira e administrativa para reduzir a razão entre o backlog de pedidos de patentes farmacêuticas e o número de examinadores.
En Brasil, si la tramitación de una patente tarda más de 10 años, este período extra se añade a la vigencia regular de 20 años. Este trabajo analiza todas las patentes farmacéuticas otorgadas por la Oficina de Patentes Brasileña (INPI) con extensión de su vigencia, y discute posteriormente algumas implicaciones para las políticas de propriedade intelectual y de salud. En promedio, las solicitudes de patentes farmacéuticas esperan siete años desde el requerimiento del examen antes de ser examinadas, lo que tarda solamente tres años y medio. Asimismo, el rol de la Agencia Nacional de Vigilancia Sanitaria (Anvisa) al dar su consentimiento previo tiene un efecto marginal para prolongar la tramitación. Por ello, la extensión de la vigencia de las patentes farmacéuticas está provocada por el número de solicitudes pendientes por examinador, lo que paraliza la tramitación por el doble de período de tiempo que cuesta examinar las solicitudes. Así pues, las soluciones apropiadas deberían centrarse en reducir el acúmulo de solicitudes pendientes por examinador en el INPI, que ha provocado la extensión de la patente en un 92% de las solicitudes farmacéuticas en tres años y meio, en promedio. Se concluye que la política de patentes farmacéuticas brasileña está sesgada hacia el titular de la patente. Este desequilibrio solo se corregirá efectivamente cuando el INPI tenga autonomía financeira y administrativa para reducir la razón entre el backlog de solicitudes de patentes farmacéuticas y el número de examinadores.
Subject(s)
Humans , Drug and Narcotic Control , Drug Industry , Brazil , Pharmaceutical Preparations , Government AgenciesABSTRACT
Resumen: Artículo de carácter reflexivo y argumentativo que busca confrontar referentes conceptuales desde la Bioética y el derecho para dar solución a estos interrogantes: ¿son los derechos de propiedad intelectual la antítesis de otros derechos? ¿Existe un conflicto de principios bioéticos en dicha tensión? ¿Cómo abordar desde la Bioética este choque de miradas? ¿Es necesario un cambio de paradigma para transformar el individualismo imperante de la contemporaneidad y evitar los daños de una guerra de rapiñas que se enmascara detrás de un eufemismo de la competencia de mercados y la propiedad intelectual? Entre argumentos, cuestionamientos y disensos se busca un abordaje a estos dilemas con un enfoque bioético. Se deja sobre la mesa la cooperación con una base de empatía y compasión para desviarse del camino del individualismo pernicioso y la voracidad subsecuente del dinero y el poder. Por ello, la Bioética como puente hacia al futuro es la disciplina llamada manifestar dicha cooperación, no solo en los ámbitos disciplinarios, sino entre los diferentes actores sociales, entre los protagonistas de esta obra, para que su final no sea trágico, sino esperanzador y saludable.
Summary: This is a reflexive and argumentative article which intention is to confront conceptual references from bioethics and the right to solve the following questions: are intellectual property rights the antithesis of other rights? Is there a conflict of bioethical principles in this discussion? How to address from Bioethics this difference in point of views? Is a paradigm shift necessary to transform the prevailing individualism of contemporaneity and avoid the damages of a war of plunder masked behind a euphemism of market competition and intellectual property? Between arguments, questions and dissents, an approach to these dilemmas is sought with a bioethical approach. Cooperation is on the table based on empathy and compassion to divert it from the path of pernicious individualism and the subsequent voracity of money and power. Therefore bioethics, as a bridge to the future is the discipline called to manifest this cooperation, not only in disciplinary areas, but between the different social stakeholders, among those main players of this work, so that its end is not tragic, but hopeful and healthy.
Resumo: Artigo reflexivo e argumentativo que busca confrontar referências conceituais da Bioética e do direito para resolver as seguintes questões: os direitos de propriedade intelectual são a antítese de outros direitos? Existe um conflito de princípios bioéticos nessa tensão? Como abordar este choque de perspectivas a partir da Bioética? É necessária uma mudança de paradigma para transformar o individualismo predominante da contemporaneidade e evitar os danos de uma briga que se mantém mascarada por trás de um eufemismo de concorrência de mercado e propriedade intelectual? Entre argumentos, perguntas e dissensos, busca-se uma abordagem desses dilemas com uma abordagem Bioética. A cooperação é deixada sobre a mesa com uma base de empatia e compaixão para se desviar do caminho do individualismo pernicioso e da subsequente voracidade do dinheiro e do poder. Portanto, a Bioética, como ponte para o futuro, é a disciplina convocada a manifestar tal cooperação, não apenas nos campos disciplinares, mas entre os diferentes atores sociais, entre os protagonistas deste trabalho, para que seu fim não seja trágico, mas esperançoso e saudável.
ABSTRACT
Este artigo tem por objetivo a realização de uma breve análise dos requisitos da patenteabilidade (novidade, atividade inventiva e aplicação industrial) e do procedimento de autorização de introdução do medicamento no mercado(AIM) no âmbito europeu e português, tendo em conta a atual crise pandêmica daCOVID-19, bem como a possibilidade (ou não) de utilização da licença obrigatória em situações pandêmicas.
This article aims to conducta brief analysis of the requirements for patentability (novelty, inventive step and industrial application) and the authorization procedure for placing the medicine on the market in the European and Portuguese scope, taking into account the current crisispandemic of COVID-19, as well as the possibility (or not) of using the mandatory license in pandemic situations.
Este artículo tiene como objetivo realizar un breve análisis de los requisitos de patentabilidad (novedad, actividad inventiva y aplicación industrial) y el procedimiento de autorización para la comercialización del medicamento en el ámbito europeo y portugués, teniendo en cuenta la crisis actual. pandemia de COVID-19, así como la posibilidad (o no) de utilizar la licencia obligatoria en situaciones de pandemia.
ABSTRACT
O direito de propriedade intelectual tem as suas exceções e os seus limites internos, previstos na lei. Nos últimos tempos, vem crescendo a discussão da sua compressão à luz de princípios gerais, como o interesse público, a liberdade de expressão ou a saúde pública. Dir-se-ia, pois, que estes direitos têm, também, uma função social, para além da proteção das prerrogativas dos seus titulares, o que é verdadeiro, sobretudo, para as patentes farmacêuticas. Grande parte desta discussão sempre passou, na verdade, pelas patentes farmacêuticas, sua concessão e exploração, em especial no que tange às patentes biotecnológicas. Esta discussão mais e mais se exacerbou quanto às patentes das vacinas destinadas ao tratamento contra a COVID-19. Não falta quem queira lançar mão dos meios previstos nas leis nacionais e internacionais para compelir às licenças obrigatórias das patentes e, até, à sua expropriação. Em causa, podem estar, no entanto, outros aspetos, como contratos mal negociados pela Comissão da União Europeia com algumas empresas farmacêuticas e os problemas logísticos na produção de vacinas. Por outro lado, centrar a discussão nas patentes poderá ser redutor, uma vez que há outros aspetos da propriedade intelectual a considerar. Contudo, a resposta estará, muito provavelmente, no equilíbrio entre os direitos dos titulares de patentes e o interesse público.
Intellectual property law has its exceptions and internal limits, as provided by law. In recent times, there has been a growing discussion of its compression in the light of general principles, such as public interest, freedom of expression or public health. It would be said, therefore, that these rights also have a social function, in addition to protecting the rights of their holders, which is especially true for pharmaceutical patents. Much of this discussion has always, in fact, passed through pharmaceutical patents, their granting and exploitation, especially regardingbiotechnological patents. This discussion has become increasinglyexacerbated regardingthe patents on vaccines intended for treatment against COVID-19. There is no shortage of people who want to use the means provided by national and international laws to compel mandatory patent licenses and even their expropriation. At issue, however, may be other aspects, such as contracts poorly negotiated by the European Union Commission with pharmaceutical companies and logistical problems in the production of vaccines. On the other hand, focusing the discussion on patents, can be reduced, there are other aspects of intellectual property to consider. However, the answer will most likely lie in the balance between the rights ofpatent holders and the public interest.
La ley de propiedad intelectual tiene sus excepciones y límites internos, según lo establece la ley. En los últimos tiempos, ha habido un creciente debate sobre su compresión a la luz de principios generales, como el interés público, la libertad de expresión o la salud pública. Se diría,por tanto, que estos derechos también tienen una función social, además de proteger los derechos de sus titulares, lo que es especialmente cierto para las patentes farmacéuticas. Gran parte de esta discusión siempre ha pasado, de hecho, por las patentes farmacéuticas, su concesión y explotación, especialmente en lo que respecta a las patentes biotecnológicas. Esta discusión se ha exacerbado cada vez más con respecto a las patentes de vacunas destinadas al tratamiento contra COVID-19. No hay escasez de personas que quieran utilizar los medios que brindan las leyes nacionales e internacionales para imponer licencias de patentes obligatorias e incluso su expropiación. Sin embargo, pueden estar en juego otros aspectos, como los contratos mal negociados por la Comisión de la Unión Europea con algunas empresas farmacéuticas y los problemas logísticos en la producción de vacunas. Por otro lado, centrar la discusión en las patentes, se puede reducir, hay otros aspectos de la propiedad intelectual a considerar. Sin embargo, lo más probable es que la respuesta esté en el equilibrio entre los derechos de los titulares de patentes y el interés público.
ABSTRACT
Resumo O texto apresenta e discute os principais aspectos relacionados à dinâmica atual da indústria de vacinas no mundo e no Brasil, com foco na demanda criada pela pandemia da COVID-19. No plano global, expõe brevemente o lugar ocupado atualmente pelo Brasil no âmbito dos BRICS e expõe e analisa as opções - identidades e diferenças - da política industrial de Brasil, China e Índia no campo das vacinas. A seguir, analisa o deslocamento da indústria de vacinas de uma situação de produção exclusiva de imunizantes para um controle majoritário da grande indústria farmacêutica. Mais adiante, recupera aspectos fundamentais recentes da indústria de vacinas no Brasil, com ênfase em Biomanguinhos/Fiocruz e no Instituto Butantan. Finalmente, discute os sucessos e limitações do mecanismo de transferência de tecnologia utilizado pelas duas instituições, bem como a relevância do compromisso historicamente assumido pelas mesmas com as políticas públicas de saúde.
Abstract The text presents and discusses the main aspects related to the current dynamics of the vaccine industry in the world and in Brazil, focusing on the demand created by the pandemic of COVID-19. At the global level, it briefly exposes the place currently occupied by Brazil within the scope of the BRICS and sets out and analyzes the options - identities and differences - of industrial policy in Brazil, China and India in the field of vaccines. Next, it analyzes the displacement of the vaccine industry, from a situation of exclusive production of immunizers to a majority control by the large pharmaceutical industry. Further on, it recovers recent fundamental aspects of the vaccine industry in Brazil, with an emphasis on Biomanguinhos / Fiocruz and the Butantan Institute. Finally, it discusses the successes and limitations of the technology transfer mechanism used by the two institutions, as well as the relevance of their historically assumed commitment to public health policies.
Subject(s)
Humans , Vaccines , COVID-19 , Brazil , China , Public Health , SARS-CoV-2 , IndiaABSTRACT
El tsunami de moralidad con que los medios de comunicación masivos distraen a la Argentina y buena parte del mundo, ni siquiera coloca entre paréntesis la conducta inmoral de la Organización Mundial de Comercio (OMC), entidad que se resiste al tratamiento y aplicación del proyecto de suspensión de patentes y derechos de propiedad intelectual (DPI) presentado al organismo por la India y Sudáfrica en octubre de 2020
The tsunami of morality with which the mass media distract Argentina and much of the world, does not even put the immoral conduct of the World Trade Organization (WTO) , an entity that resists the treatment and application of the project for the suspension of patents and intellectual property rights (IPR) submitted to the organization by India and South Africa in October 2020
Subject(s)
Intellectual Property , Patent , COVID-19 , Mass MediaABSTRACT
Las patentes no se publican con la misma celeridad que los artículos científicos porque tiene que transcurrir como mínimo 18 meses de examen de la invención entre su solicitud y el registro público de su concesión en forma de documento de patente. Por eso, el mayor número de patentes publicadas hasta ahora abarca los anteriores coronavirus que afectan a humanos, como son el Síndrome Respiratorio Agudo Severo y el Síndrome Respiratorio de Oriente Medio, de los cuales sí existen patentes de técnicas de diagnóstico, tratamientos e incluso vacunas, así como un menor número de patentes relacionadas con la actual pandemia causada por la COVID-19 por el poco tiempo transcurrido y la alta virología de la enfermedad. La presente de investigación tuvo como objetivo analizar el comportamiento de las invenciones solicitadas y concedidas sobre COVID-19 que han sido registradas en la Oficina Internacional de Patentes de los Estados Unidos. El estudio, por su naturaleza, empleó un enfoque mixto de la investigación, donde se articularon de forma sistémica métodos de corte cualitativo y cuantitativo que permitieron la complementación de los diferentes análisis métricos. Los resultados mostraron que el mayor poderío tecnológico se agrupa en titulares de Estados Unidos, seguidos por Irán, Israel, Bulgaria, Canadá y Reino Unido, y que el número de investigaciones sobre COVID -19 se centra en: técnicas para su identificación y diagnóstico; sistemas informáticos; péptidos; radioterapia; reconocimiento de datos modelos computacionales; mutación e ingeniería genética; colorimetría; procesamiento de datos eléctricos digitales; entre otros temas, que conforman la vanguardia tecnológica innovadora que existe hoy en el mundo sobre la COVID -19(AU)
Patents are not published as quickly as scientific articles because at least 18 months of examination of the invention must elapse between its application and the public record of its grant in the form of a patent document. For this reason, the largest number of patents published so far cover the previous coronaviruses that affect humans, such as Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome, of which there are patents for diagnostic techniques, treatments and even vaccines. There are fewer patents related to the current pandemic caused by COVID-19 due to the short time that has elapsed and the high virology of the disease. The objective of this research was to analyze the behavior of the requested and granted inventions on COVID-19 that have been registered in the United States International Patent Office. The study by its nature used a mixed approach to research where qualitative and quantitative cutting methods were articulated in a systemic way that allowed the complementation of the different metric analyzes. The results showed that the greatest technological power is clustered in the headlines of the United States, followed by Iran, Israel, Bulgaria, Canada and the United Kingdom, and that the number of investigations on COVID-19 are focused on techniques for its identification and diagnosis, in: computer systems; peptides; radio-therapy; data recognition; computational models; mutation and genetic engineering; colorimetry; digital electrical data processing; among other topics that make up the innovative technological vanguard that exist today in the world on COVID -19(AU)
Subject(s)
Humans , Patents as Topic/statistics & numerical data , Inventions , COVID-19 , United States , Retrospective StudiesABSTRACT
Objective:This study analyzes COVID-19 prevention and treatment technology patents from 103 countries and regions worldwide, in order to have a good grasp of the most-current trends in COVID-19 prevention and treatment technology research worldwide, discuss the research directions of such technologies, provide theoretical foundations for interdisciplinary and multi-team cooperation.Methods:The retrieval strategies were constructed utilizing the retrieval and analysis system by the Regional Patent Information Service (Nanjing) Center of The State Intellectual Property Office and IncoPat's scientific and technological innovation platform, using third-level branches as the unit and separating the retrieval and proof processes, the queries built using IPC classification numbers and key words; the search was limited to invention patents, with utility models and designs excluded.Results:On February 14, 2020, there had been a total number of 136 087 invention patent applications for COVID-19 prevention and treatment technologies globally. In terms of the country of origin, the U. S. ranked first with 56 095 patents, followed by China (18 096). In terms of technical field, the top three were chemical therapeutic agents (47 634), vaccines (47 248) and diagnostic tests (12 991), with the U. S. possessing absolutely advantageous patent portfolios in all three fields. The applicants were mainly comprised of large enterprises abroad and universities and research institutes in China.Conclusions:China′s COVID-19 related patent applications are relatively scattered. In the field of chemotherapy, there is room for improvement compared with the advanced countries, and cooperation between scientific institutions and enterprises is insufficient. Therefore, China should further increase investment in chemical drug research and development and seize the opportunity to actively promote the research and development of vaccine technology. On the other hand, we need to consolidate the technical advantages and product advantages of epidemic prevention and control which are already accumulated, and strengthen the protection and layout of intellectual property rights. Furthermore, the technological innovation system combining production, education and research is the breakthrough point to encourage enterprises to become the subject of technological innovation.Last but not least, we should build a service platform for the transfer and transformation of scientific and technological achievements to enhance intellectual property rights and promote the transformation of scientific and technological achievements.
ABSTRACT
Objective:To explore the medication regularity and prescription rule of Chinese herbal medicine in the treatment of cardiac failure.Methods:The China Patent Publication Notice of the State Intellectual Property Office (http://epub.sipo.gov.cn/) was rearched and retrievedfor Chinese herbal medicine for the treatment of heart failure. The Traditional Chinese Medicine (TCM) inheritance support system (V 2.5) was used to input the prescription information and establish the database. The association rules, mutual information method, entropy clustering of complex systems and other data mining methods were used for commonly used drugs, combination rule and new prescription of core group.Results:A total of 101 prescriptions were included, involving 316 drugs. The frequency of commonly used drugs were Astragali Radix (59.41%), Poria (41.58%), Salviae Miltiorrhizae Radix et Rhizoma (40.59%), Descurainiae Semen Lepidii Semen (34.65%), Aconiti Lateralis Radix Praeparata (33.66%), and the medicinal properties were mainly warm, and the sweet taste. The main flavors weresweet, bitterness, and pungency, and the main sources of meridians belonged to liver, spleen, heart, lungs and kidneys. The most commonly used drug combinations contribute to supplement Qi, invigorate blood circulation and stasis, warm Yang, remove moisture. There were 12 core drug groups and 6 new prescriptions for heart failure. Conclusions:Analysis on formulas for heart failure shows that the prescriptions focus on supplementing qi and activating blood circulation, warming Yang reducing dampness, invigorating spleen, and nourishing Yin, dispel turbid, solid Yang. It can provide reference for clinical treatment to improve curative effect and standardize prescription medication.
ABSTRACT
El recurso más finito de un científico hoy es el tiempo. Un minuto sin una vacuna específica, un tratamiento adecuado o un protocolo seguro significa miles de muertes. A partir de esta necesidad, la presente investigación tuvo como objetivo caracterizar las funcionalidades del Observatorio Métrico de Coronavirus desarrollado por la Universidad de Pinar del Río Hermanos Saíz Montes de Oca como herramienta para el monitoreo, la compilación, el análisis y la visualización de la información procedente de artículos científicos arbitrados y de patentes de invención registradas en bases de datos internacionales sobre Coronavirus. Para su desarrollo se utilizaron diferentes métodos y procedimientos que permitieron, de conjunto con la tecnología aplicada y los indicadores métricos definidos, disponer de una plataforma dinámica que reduce significativamente los tiempos de búsqueda e interpretación de la información relevante sobre el dominio científico y tecnológico Coronavirus, lo que supone ser también un aporte oportuno y valioso que contribuye a la búsqueda de soluciones ante esta letal pandemia. Este Observatorio es un espacio de transformación de la información en conocimiento para la acción investigativa y la toma de decisiones. Es un resultado científico que contribuye al encadenamiento de la Academia con el sector investigativo y productivo de la Biotecnología en el país, conducido por los intereses y prioridades del Gobierno al servicio de toda la sociedad cubana(AU)
The finest resource for a scientist today is time. One minute without a specific vaccine, proper treatment, or a safe protocol means thousands of deaths. Based on this need, this research aims to show the functionalities of the Coronavirus Metric Observatory developed by the Pinar del Río University Hermanos Saíz Montes de Oca as a tool that allows the monitoring, compilation, analysis and visualization of information from peer-reviewed scientific papers and invention patents registered in international databases on Coronavirus. For its development, different methods and procedures were used that, together with the applied technology and the defined metric indicators, made it possible to have a dynamic platform that significantly reduces the search and interpretation times for relevant information on the scientific and technological domain Coronavirus. Having a dynamic platform that significantly reduces the time for analysis and interpretation of relevant information is also a timely and valuable contribution that contributes to the search for solutions to this deadly pandemic. This Observatory is a space for transforming information into knowledge for action. It is a scientific result that contributes to linking the Academy with the research and productive sector of Biotechnology in the country, driven by the interests and priorities of the Government at the service of all Cuban society(AU)